DE10244907A1 - Orally administered dietetic food, nutritional supplement or medicament, especially for improving sporting performance, comprising mixture of L-carnitine and eicosapentaenoic and docosahexaenoic acids - Google Patents
Orally administered dietetic food, nutritional supplement or medicament, especially for improving sporting performance, comprising mixture of L-carnitine and eicosapentaenoic and docosahexaenoic acids Download PDFInfo
- Publication number
- DE10244907A1 DE10244907A1 DE10244907A DE10244907A DE10244907A1 DE 10244907 A1 DE10244907 A1 DE 10244907A1 DE 10244907 A DE10244907 A DE 10244907A DE 10244907 A DE10244907 A DE 10244907A DE 10244907 A1 DE10244907 A1 DE 10244907A1
- Authority
- DE
- Germany
- Prior art keywords
- mixture according
- substance mixture
- carnitine
- omega
- fatty acids
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 21
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 title claims abstract description 15
- 235000005911 diet Nutrition 0.000 title claims 2
- 230000000378 dietary effect Effects 0.000 title claims 2
- 235000015872 dietary supplement Nutrition 0.000 title claims 2
- 239000003814 drug Substances 0.000 title claims 2
- 235000013305 food Nutrition 0.000 title claims 2
- 235000020673 eicosapentaenoic acid Nutrition 0.000 title abstract description 11
- 235000020669 docosahexaenoic acid Nutrition 0.000 title abstract description 7
- DVSZKTAMJJTWFG-UHFFFAOYSA-N docosa-2,4,6,8,10,12-hexaenoic acid Chemical class CCCCCCCCCC=CC=CC=CC=CC=CC=CC(O)=O DVSZKTAMJJTWFG-UHFFFAOYSA-N 0.000 title 1
- 235000020660 omega-3 fatty acid Nutrition 0.000 claims abstract description 13
- 229940012843 omega-3 fatty acid Drugs 0.000 claims abstract description 13
- 239000006014 omega-3 oil Substances 0.000 claims abstract description 13
- 239000000126 substance Substances 0.000 claims description 9
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 7
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 6
- 235000019154 vitamin C Nutrition 0.000 claims description 4
- 239000011718 vitamin C Substances 0.000 claims description 4
- 235000019165 vitamin E Nutrition 0.000 claims description 4
- 239000011709 vitamin E Substances 0.000 claims description 4
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 3
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims description 3
- 229930003268 Vitamin C Natural products 0.000 claims description 3
- 229930003427 Vitamin E Natural products 0.000 claims description 3
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 3
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 3
- 229910052711 selenium Inorganic materials 0.000 claims description 3
- 239000011669 selenium Substances 0.000 claims description 3
- 229940046009 vitamin E Drugs 0.000 claims description 3
- 239000011701 zinc Substances 0.000 claims description 3
- 229910052725 zinc Inorganic materials 0.000 claims description 3
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 claims description 2
- 239000011651 chromium Substances 0.000 claims description 2
- 229910052804 chromium Inorganic materials 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims 2
- 239000000843 powder Substances 0.000 claims 2
- MIDXCONKKJTLDX-UHFFFAOYSA-N 3,5-dimethylcyclopentane-1,2-dione Chemical compound CC1CC(C)C(=O)C1=O MIDXCONKKJTLDX-UHFFFAOYSA-N 0.000 claims 1
- 241000251468 Actinopterygii Species 0.000 claims 1
- 241000195493 Cryptophyta Species 0.000 claims 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims 1
- 229930064664 L-arginine Natural products 0.000 claims 1
- 235000014852 L-arginine Nutrition 0.000 claims 1
- 241001529742 Rosmarinus Species 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 239000003708 ampul Substances 0.000 claims 1
- 239000003963 antioxidant agent Substances 0.000 claims 1
- 235000006708 antioxidants Nutrition 0.000 claims 1
- 235000013736 caramel Nutrition 0.000 claims 1
- 239000008298 dragée Substances 0.000 claims 1
- 235000021323 fish oil Nutrition 0.000 claims 1
- 230000037406 food intake Effects 0.000 claims 1
- 239000008187 granular material Substances 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 230000003647 oxidation Effects 0.000 claims 1
- 238000007254 oxidation reaction Methods 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
- 229930003799 tocopherol Natural products 0.000 claims 1
- 229960001295 tocopherol Drugs 0.000 claims 1
- 239000011732 tocopherol Substances 0.000 claims 1
- 235000010384 tocopherol Nutrition 0.000 claims 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims 1
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 abstract description 10
- 229960005135 eicosapentaenoic acid Drugs 0.000 abstract description 10
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 abstract description 10
- DVSZKTAMJJTWFG-SKCDLICFSA-N (2e,4e,6e,8e,10e,12e)-docosa-2,4,6,8,10,12-hexaenoic acid Chemical compound CCCCCCCCC\C=C\C=C\C=C\C=C\C=C\C=C\C(O)=O DVSZKTAMJJTWFG-SKCDLICFSA-N 0.000 abstract description 2
- GZJLLYHBALOKEX-UHFFFAOYSA-N 6-Ketone, O18-Me-Ussuriedine Natural products CC=CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O GZJLLYHBALOKEX-UHFFFAOYSA-N 0.000 abstract description 2
- KAUVQQXNCKESLC-UHFFFAOYSA-N docosahexaenoic acid (DHA) Natural products COC(=O)C(C)NOCC1=CC=CC=C1 KAUVQQXNCKESLC-UHFFFAOYSA-N 0.000 abstract description 2
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 description 8
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- 229940090949 docosahexaenoic acid Drugs 0.000 description 4
- 210000003205 muscle Anatomy 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 239000003623 enhancer Substances 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 230000035882 stress Effects 0.000 description 3
- 239000004475 Arginine Substances 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 239000011573 trace mineral Substances 0.000 description 2
- 235000013619 trace mineral Nutrition 0.000 description 2
- 230000007704 transition Effects 0.000 description 2
- RGJOEKWQDUBAIZ-IBOSZNHHSA-N CoASH Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCS)O[C@H]1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-IBOSZNHHSA-N 0.000 description 1
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 1
- ODUCDPQEXGNKDN-UHFFFAOYSA-N Nitrogen oxide(NO) Natural products O=N ODUCDPQEXGNKDN-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- RGJOEKWQDUBAIZ-UHFFFAOYSA-N coenzime A Natural products OC1C(OP(O)(O)=O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-UHFFFAOYSA-N 0.000 description 1
- 239000005516 coenzyme A Substances 0.000 description 1
- 229940093530 coenzyme a Drugs 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- KDTSHFARGAKYJN-UHFFFAOYSA-N dephosphocoenzyme A Natural products OC1C(O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 KDTSHFARGAKYJN-UHFFFAOYSA-N 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 150000004668 long chain fatty acids Chemical class 0.000 description 1
- 150000004667 medium chain fatty acids Chemical class 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 210000001700 mitochondrial membrane Anatomy 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
- A23L33/12—Fatty acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Inorganic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Die Erfindung betrifft die Verwendung eines Leistungsförderer für Sportler zur oralen Einnahme bestehend aus einem Gemisch aus den Omega-3-Fettsäuren EPA (Eicosapentaensäure) und DHA (Docosahexaensäure) und L-Carnitin als wirksame Substanzen, sowie gegebenenfalls zusätzlichen Stoffen wie antioxidative Vitamine, Aminosäuren und Spurenelemente.The invention relates to the use a performance enhancer for athletes for oral consumption consisting of a mixture of the omega-3 fatty acids EPA (Eicosapentaenoic acid) and DHA (docosahexaenoic acid) and L-carnitine as active substances, and optionally additional ones Substances like antioxidative vitamins, amino acids and trace elements.
Eine Übersäuerung der Muskulatur (Lactatanstieg) ist die natürliche Begrenzung der Leistungsfähigkeit von Sportlern.Acidification of the muscles (increase in lactate) is the natural one Limitation of performance by athletes.
Die der Erfindung zugrunde liegende Aufgabe ist es, einen Leistungsförderer zur Verfügung zu stellen, der den Lactatanstieg in der Muskulatur verzögert und die Muskeln länger mit ausreichend Sauerstoff versorgt, so dass Sportler in der Ausdauer- und Langzeitbelastung über eine längere Zeit leistungs- und belastungsfähig bleiben. Das erfindungsgemäße Gemisch muss in der Langzeitanwendung bei Sportlern in ausreichend großen Dosen verabreicht werden können, ohne dass unerwünschte Nebenwirkungen weder kurz- noch langfristig auftreten, und darf nicht unter die Doping-Richtlinien fallen.The basis of the invention The job is to be a performance enhancer to disposal which delays the increase in lactate in the muscles and the muscles longer supplied with sufficient oxygen so that athletes in endurance and Long-term exposure over a longer one Time efficient and resilient stay. The mixture according to the invention in long-term use in athletes in sufficiently large doses can be administered without unwanted Side effects neither occur in the short nor long term, and may do not fall under the doping guidelines.
Die in dem erfindungsgemäßen Gemisch enthaltenen Omega-3-Fettsäuren Eicosapentaensäure EPA) und Docosahexaensäure (DHA) sorgen für eine hohe Zell- und Gefäßwand-Fluidität und -Flexibilität, so dass eine optimale bedarfsgerechte Mikrozirkulation, gerade unter Belastungsbedingungen, sichergestellt wird. Davon profitieren sowohl die Erythrozyten wie die Kapillarwand mit einer wünschenswert hohen Sauerstoffverfügbarkeit, auch bei beginnender Dehydration (stabile maximale Sauerstoffaufnahmefähigkeit). Als Resultat wird so einer überschießenden Lactatbildung in der Muskulatur effizient vorgebeugt, bezogen auf die aktuelle genetisch und trainingsbedingt vorgegebene aerobe Kapazität und Leistungsfähigkeit.The contained in the mixture according to the invention Omega-3 fatty acids eicosapentaenoic acid EPA) and docosahexaenoic acid (DHA) ensure high cell and vascular wall fluidity and flexibility, so that Optimal microcirculation tailored to requirements, especially under stress conditions, is ensured becomes. Both the erythrocytes and the capillary wall benefit from this with a desirable high oxygen availability, even when dehydration begins (stable maximum oxygen absorption capacity). The result is an excessive lactate formation efficiently prevented in the muscles, based on the current Genetically and training-related aerobic capacity and performance.
Das in dem Erfindungsgemisch enthaltene L-Carnitin ist ein Biocarrier für mittel- und langkettige Fettsäuren durch die innere Mitochondrienmembran. L-Carnitin hat unter Ausdauerbelastung im aeroben-anaeroben Übergangsbereich eine gesicherte Coenzym A – Entlastungsfunktion. Dadurch kann der Übergangsbereich und noch ein wenig darüber hinaus intensitätsbezogen voll ausgereizt werden, ohne dass es zu einem deutlichen und damit dann leistungsminderndem Lactatanstieg kommt. Der Sportler kann höhere Intensitäten gehen, ohne einen abrupten Leistungseinbruch befürchten zu müssen, da die ökonomische aerobe Zuckerverbrennung beibehalten werden kann. Gleichzeitig wird so, bezogen auf den Energiestoffwechsel und die Sauerstoffversorgung, auch eine unerwünschte lange Regenerationsdauer vermieden.The L-carnitine contained in the inventive mixture is a biocarrier for medium and long chain fatty acids through the inner mitochondrial membrane. L-carnitine is under endurance in the aerobic-anaerobic transition area a secured coenzyme A - relief function. This allows the transition area and a little bit more about that also related to intensity be fully maxed out without making it clear and hence then performance-reducing lactate increase comes. The athlete can higher intensities go without having to fear an abrupt drop in performance because the economic aerobic sugar burning can be maintained. At the same time so, based on energy metabolism and oxygen supply, also an undesirable long regeneration times avoided.
Darüber hinaus wird ein positiver Beitrag der Omega-3-Fettsäuren auf den Blutdruck, Arrhytmien des Herzens (Ausdauersportler sind davon oft betroffen), das Herzinfarkt- und Schlaganfallrisiko für Untrainierte unter plötzlich hoher Belastung und auf entzündliche Prozesse, wie sie unter Ausdauerbelastung auftreten, sichergestellt.It also becomes a positive one Contribution of omega-3 fatty acids on blood pressure, arrhythmias of the heart (endurance athletes are often affected), the risk of heart attack and stroke for untrained people under suddenly high stress and inflammatory Processes that occur under endurance stress are ensured.
Diese Aufgabe wird durch den erfindungsgemäßen Leistungsförderer zur oralen Verabreichung gelöst, der durch einen Gehalt an 1–3 g Omega-3-Fettsäuren (EPA und DNA) und 1–3 g L-Carnitin pro Tagesdosis gekennzeichnet ist.This object is achieved by the performance promoter according to the invention oral administration solved, which by a content of 1-3 g Omega-3 fatty acids (EPA and DNA) and 1-3 g of L-carnitine per daily dose.
In einer Gruppe von Radfahrern, die bislang nur L-Carnitin zu sich nahmen, wurde mit einer erfindungsgemäßen Supplementation von Omega-3-Fettsäuren zum L-Carnitin das erfindungsgemäße Gemisch von Omega-3-Fettsäuren mit L-Carnitin getestet. Die Ausdauer wurde gegenüber der alleinigen Einnahme von L-Carnitin erheblich gesteigert, der aerobe Bereich wurde viel länger gehalten und die Regenerationsphase wurde erheblich verkürzt.In a group of cyclists who So far only L-carnitine was ingested with a supplement according to the invention of omega-3 fatty acids the mixture according to the invention for L-carnitine of omega-3 fatty acids tested with L-carnitine. The endurance was compared to the sole intake of L-carnitine significantly increases the aerobic Area became much longer held and the regeneration phase was shortened considerably.
Erstaunlicherweise ist die kombinierte Anwendung von Omega-3-Fettsäuren mit L-Carnitin ein hochwirksamer Leistungsförderer, was nach dem bisherigen Erfahrungstand von L-Carnitin allein die Wirkung von L-Carnitin noch weiter steigert.Amazingly, the combined one Use of omega-3 fatty acids with L-carnitine a highly effective performance enhancer, which according to the previous Experience of L-carnitine alone the effect of L-carnitine increases even further.
Eine bevorzugte erfindungsgemäße Ausgestaltung des Omega-3-Fettsäuren (EPA/DHA) – L-Carnitin – Gemisches sieht wie folgt aus:A preferred embodiment according to the invention of omega-3 fatty acids (EPA / DHA) - L-Carnitine - Mixture looks like this:
Beispiel 1 (Tagesportion):Example 1 (daily portion):
1–3 g L-Carnitin und 1–3 g der Omega-3-Fettsäuren EPA/DHA im bevorzugten Verhältnis 2 zu 3.1-3 g of L-carnitine and 1-3 g of Omega-3 fatty acids EPA / DHA in the preferred ratio 2 to 3.
Ausdauersportler unterliegen einem erhöhten oxidativen Stress mit der vermehrten Bildung von freien Radikalen. Entsprechend empfiehlt es sich in einer weiteren Ausgestaltung der Erfindung das EPA/DHA-L-Carnitin Gemisch anzureichern mit: den anti-oxidativen Vitaminen C und E, und/oder den für die Immunabwehr wichtigen Spurenelementen Zink und Selen (hier besteht eine Unterversorgung), sowie und/oder der Stickoxid (NO) liefernden Aminosäure Arginin.Endurance athletes are subject to one increased oxidative stress with the increased formation of free radicals. Accordingly, it is recommended in a further embodiment of the Invention to enrich the EPA / DHA-L-carnitine mixture with: the anti-oxidative Vitamins C and E, and / or those important for the immune system Trace elements zinc and selenium (there is an undersupply here), as well as and / or the nitrogen oxide (NO) providing amino acid arginine.
Beispiel 2 (Tagesportion):Example 2 (daily portion):
Mischung wie Beispiel 1, aber zusätzlich mit 200 mg Vitamin C, 100 mg Vitamin E versehen.Mixture as example 1, but additionally with 200 mg of vitamin C, 100 mg of vitamin E.
Beispiel 3 (Tagesportion):Example 3 (daily portion):
Mischung wie Beispiel 2, aber zusätzlich mit 15 mg Selen und 15 mg Zink versehen.Mixture as example 2, but additionally with 15 mg selenium and 15 mg zinc.
Beispiel 4 (Tagesportion):Example 4 (daily portion):
Mischung wie Beispiel 3, aber zusätzlich mit 200 μg Chrom (bei Diabetikern Typ 2) versehen.Mixture as example 3, but additionally with 200 μg chromium (at Type 2 diabetes.
Beispiel 5 (Tagesportion):Example 5 (daily portion):
Mischung wie Beispiel 4, aber zusätzlich mit 5 g Arginin versehen.Mixture as example 4, but additionally with 5 g arginine.
Claims (8)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10244907A DE10244907A1 (en) | 2002-09-25 | 2002-09-25 | Orally administered dietetic food, nutritional supplement or medicament, especially for improving sporting performance, comprising mixture of L-carnitine and eicosapentaenoic and docosahexaenoic acids |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10244907A DE10244907A1 (en) | 2002-09-25 | 2002-09-25 | Orally administered dietetic food, nutritional supplement or medicament, especially for improving sporting performance, comprising mixture of L-carnitine and eicosapentaenoic and docosahexaenoic acids |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE10244907A1 true DE10244907A1 (en) | 2004-04-15 |
Family
ID=32009919
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE10244907A Withdrawn DE10244907A1 (en) | 2002-09-25 | 2002-09-25 | Orally administered dietetic food, nutritional supplement or medicament, especially for improving sporting performance, comprising mixture of L-carnitine and eicosapentaenoic and docosahexaenoic acids |
Country Status (1)
| Country | Link |
|---|---|
| DE (1) | DE10244907A1 (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2316263A1 (en) * | 2005-12-21 | 2009-04-01 | Proyecto Empresarial Brudy, S.L. | Use of dha, epa or dha-derived epa for treating pathology associated with cellular oxidative damage |
| WO2012085671A3 (en) * | 2010-12-21 | 2013-04-11 | Omegatri As | Antioxidants in fish oil powder and tablets |
-
2002
- 2002-09-25 DE DE10244907A patent/DE10244907A1/en not_active Withdrawn
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2316263A1 (en) * | 2005-12-21 | 2009-04-01 | Proyecto Empresarial Brudy, S.L. | Use of dha, epa or dha-derived epa for treating pathology associated with cellular oxidative damage |
| WO2012085671A3 (en) * | 2010-12-21 | 2013-04-11 | Omegatri As | Antioxidants in fish oil powder and tablets |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60119919T2 (en) | FREE AMINOIC COMPOSITION | |
| JP3512198B2 (en) | Two-phase preparation | |
| US20080233245A1 (en) | Liquid nutrient composition for improving performance | |
| US20090011012A1 (en) | Fatty acid compositions and methods of use | |
| JP2009132721A (en) | Preparation for improved dietary utilization | |
| KR20180016380A (en) | Fast mimic and improved diets for the treatment of hypertension and lipid disorders | |
| AU2008301699B2 (en) | Composition Comprising Sesamin Component and Vitamin B1 Component | |
| KR20150101458A (en) | Synergistic dietary supplement for enhancing physical performance | |
| AU2008301694B2 (en) | Compositions Containing Sesamin-Class Compound(s) and Arachidonic Acid Class Compound(s) | |
| Sanz et al. | Branched chain amino acids and sports nutrition and energy homeostasis | |
| TW501914B (en) | Composition having capability of removing risk factor during exercise | |
| DE20205184U1 (en) | Blood lipid lowerers for oral use | |
| DE10244907A1 (en) | Orally administered dietetic food, nutritional supplement or medicament, especially for improving sporting performance, comprising mixture of L-carnitine and eicosapentaenoic and docosahexaenoic acids | |
| DE20214827U1 (en) | Composition useful as dietetic food, nutritional supplement or medicament for enhancing sports performance comprises L-carnitine and omega-3 fatty acids | |
| JPH02243622A (en) | Fat and oil composition for lowering cholesterol in blood | |
| JP4569802B2 (en) | Method for producing an ionized mineral-binding supplement mainly composed of vitamins | |
| CN1679593A (en) | Composite preparation containing alpha-linolenic acid free acid, soybean phospholipid and vitamin E | |
| JP2007161703A (en) | Compound with antifatigue effect and compound with endurance-enhancing effect and food/drink containing the same | |
| RU2284707C1 (en) | Bioactive food supplement | |
| JP4997514B2 (en) | Antihypertensive agent | |
| JP7356833B2 (en) | Peripheral thermostimulant | |
| JPS6349985B2 (en) | ||
| JP2007230989A (en) | Endurance enhancing and anti-fatigue agent | |
| WO1998008521A1 (en) | Vitamine preparations for reducing oxygen consumption during physical efforts | |
| JP2006282644A (en) | Fatigue recovery agent |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| OR8 | Request for search as to paragraph 43 lit. 1 sentence 1 patent law | ||
| 8105 | Search report available | ||
| 8139 | Disposal/non-payment of the annual fee |